Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, 01877) has restructured its board-level Strategic Committee into a “Strategic and ESG Committee”, effective 13 March 2026, to integrate environmental, social and governance (ESG) oversight into long-term corporate strategy and investment decisions. Committee membership, tenure and other organisational parameters remain unchanged; only the mandate is broadened to include ESG responsibilities.

The board also approved the formulation of Remuneration Policies for Directors and Senior Management aimed at establishing a more systematic incentive and restraint mechanism. Implementation of the remuneration framework is subject to shareholder approval via ordinary resolution at the forthcoming general meeting.

Revised terms of reference for the Strategic and ESG Committee and the new remuneration policies will be published on the company’s website, as well as on the Hong Kong and Shanghai stock exchange platforms.